EGFR and non-small cell lung carcinoma: To date, following the positive disease-free survival (DFS) and overall survival (OS) results of the ADAURA trial, adjuvant osimertinib for 3 years has become the standard treatment option in patients with stage IB–III resected NSCLC with EGFR common activating mutations (exon 19 deletions or exon 21 p.L858R point mutation), after optional adjuvant chemotherapy [29].